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Abstract 
 
Identification of the skin sensitisation hazard of chemicals has traditionally relied on the use of animals. Progress in the 
development of alternative methods has been prompted by the increasing knowledge of the key biological mechanisms 
underlying this human health effect, as summarised in the OECD report on: "The Adverse Outcome Pathway (AOP) for Skin 
Sensitisation Initiated by Covalent Binding to Proteins". Within this AOP the activation of dendritic cells (DC), typically 
assessed by expression of cell surface markers, chemokines and cytokines, is considered to be a key event. Therefore, test 
methods able to provide information on the ability of a chemical to up-regulate markers of DC activation may contribute 
to skin sensitisation hazard assessment. The human Cell Line Activation Test (h-CLAT) measures the upregulation of the 
CD86 and CD54 markers of DC activation in THP-1 cells, a human monocytic leukemia cell line. The test method has 
undergone a validation study addressing the test method's transferability and within- and between-laboratory 
reproducibility. Following independent peer-review by the EURL ECVAM's Scientific Advisory Committee (ESAC) and having 
considered input from regulators, stakeholders, international partners and the general public, EURL ECVAM concluded that 
the h-CLAT test method should prove valuable within Integrated Approaches to Testing and Assessment (IATA) for hazard 
assessment. The h-CLAT may also be able to contribute to the assessment of sensitising potency, however it is recognised 
that further efforts are required to explore how h-CLAT data may contribute to potency assessment. 
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Background to EURL ECVAM Recommendations  
The aim of a EURL ECVAM Recommendation is to provide EURL ECVAM views on the validity of 
the test method in question, to advise on possible regulatory applicability, limitations and 
proper scientific use of the test method, and to suggest possible follow-up activities in view of 
addressing knowledge gaps. 
During the development of its Recommendations, EURL ECVAM consults with its advisory body 
for Preliminary Assessment of Regulatory Relevance (PARERE) and its EURL ECVAM Stakeholder 
Forum (ESTAF). Moreover, EURL ECVAM consults with other Commission services and its 
international validation partner organisations of the International Cooperation on Alternative 
Test Methods (ICATM). Before finalising its Recommendations, EURL ECVAM also invites 
comments from the general public and, if applicable, from the test method submitter. 
 
 
 
 
 
 
Enquiries related to this EURL ECVAM Recommendation should be sent to: 
 
EU Reference Laboratory for Alternatives to Animal Testing 
European Commission DG Joint Research Centre, 
Institute for Health and Consumer Protection, 
Via E. Fermi 2749, 
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Executive Summary 
The human Cell Line Activation Test (h-CLAT) for skin sensitisation testing was developed by Kao 
Corporation and Shiseido (Japan). With a view to facilitating its use as a component of 
integrated approaches to assessing the skin sensitisation potential of chemicals, EURL ECVAM 
coordinated a validation study to assess the reliability of the h-CLAT method and to gain some 
preliminary insight into its predictive capacity. On completion of the study, EURL ECVAM 
requested ESAC to conduct a scientific peer review of the validation study report and the 
resulting ESAC opinion was delivered in May 2014. Following consideration of the ESAC opinion 
EURL ECVAM makes the following observations and recommendations: 
1) The h-CLAT addresses one of the key events of the skin sensitisation Adverse Outcome 
Pathway (AOP) by measuring markers of dendritic cell (DC) activation in THP-1 cells, a 
human monocytic leukemia cell line. Therefore information generated by the h-CLAT is 
considered relevant for the assessment of the skin sensitisation potential of chemicals.  
2) The validation study demonstrated that the h-CLAT test method is transferable to 
laboratories experienced in cell culture techniques and flow cytometry analysis. The within-
laboratory and between-laboratory reproducibly, as characterised on the basis of 
concordant classifications of the chemicals employed (n=15 and n=24 respectively), were 
both in the order of 80%.  
3) The accuracy of h-CLAT to discriminate sensitisers from non-sensitisers was calculated to be 
76% (sensitivity 81% and specificity 66%) with the chemicals tested (n=24). However this 
result is only an approximation since the validation study was clearly not designed to fully 
assess the predictive capacity of the h-CLAT as a stand-alone method. Published information 
actually reports a higher accuracy (80%) for a larger set of chemicals (n=143; Takenouchi et 
al., 2013).  
4) Based on the outcome of the validation study and reports from the scientific literature, data 
generated with the h-CLAT method should prove valuable as part of Integrated Approaches 
to Testing and Assessment (IATA) together with complementary information (e.g. in 
chemico or other in vitro data, QSAR or read-across predictions).   
5) Besides providing information that contributes to the assessment of the skin sensitisation 
potential of chemicals, the h-CLAT assay also generates concentration-response information 
that may contribute to the assessment of potency. Nevertheless, additional work is still 
required to determine to which extent h-CLAT results can contribute to potency prediction. 
6) The h-CLAT method should be further assessed with respect to its response to chemicals 
that need to be activated (e.g. through biotransformation or auto-oxidation) before eliciting 
their sensitisation effect, and to its applicability to chemical mixtures and polymers.  
7) EURL ECVAM fully supports the development of an OECD Test Guideline for the h-CLAT. 
8) Respecting the provisions of Directive 2010/63/EU (EU, 2010) on the protection of animals 
used for scientific purposes, h-CLAT data should be considered before embarking on animal 
experiments for assessing skin sensitisation potential. As described in Annex XI of the 
REACH Regulation (EC, 2006), h-CLAT data may be used to adapt the standard information 
requirement in the context of Weight-of-Evidence (WoE) judgments (point 1.2) or by the 
use of in vitro methods (point 1.4). 
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1. Introduction 
1) The assessment of skin sensitisation potential is an important component in the safety 
evaluation of substances and represents a standard information requirement of legislation 
on chemicals in the EU. These include the Classification Labelling and Packaging of 
substances and mixtures (CLP) Regulation (EC, 2008a), the REACH Regulation, the Plant 
Protection Products (PPP) Regulation (EC, 2009a), the Biocidal Products Regulation (EU, 
2012) and the Cosmetics Regulation (EC, 2009b). Determining skin sensitisation hazard 
according to the Globally Harmonised System to Classification and Labelling (GHS) is actually 
sufficient to satisfy the majority of regulatory needs (EURL ECVAM, 2013a). However, a 
more complete characterisation of the potency of a skin sensitiser with regard to both 
induction as well as elicitation of contact dermatitis is often required for classification of 
mixtures, appropriate risk management measures (e.g. setting of appropriate exposure 
levels) and eventually a full risk assessment.  
2) Traditionally, skin sensitisation hazard assessment has involved the use of laboratory 
animals. In the framework of the Organisation for Economic Cooperation and Development 
(OECD) and the EU Test Methods Regulation (EC, 2008b), there are four accepted 
guidelines, describing: the Buehler Test and Guinea-pig Maximisation Test (TG406 OECD, 
1992; EU test method B.6), the Local Lymph Node Assay (TG429 OECD, 2010a; EU test 
method B.42) and its non-radio-isotopic variants, the Local Lymph Node Assay: DA (TG 442A 
OECD, 2010b) and the Local Lymph Node Assay: BrdU Elisa (TG 442B OECD, 2010c). 
Following the ESAC peer review of the validation studies and the publication of the EURL 
ECVAM Recommendations on the in chemico Direct Peptide Reactivity Assay (DPRA) (EURL 
ECVAM, 2013b) and the in vitro KeratinoSens test method (EURL ECVAM, 2014a), OECD 
Test Guidelines on these two assays have been developed and are in the acceptance 
process. 
3) The key biological events underpinning the skin sensitisation process are well established 
and have been summarised in the OECD report on "The Adverse Outcome Pathway (AOP) 
for Skin Sensitisation Initiated by Covalent Binding to Proteins" (OECD, 2012a, 2012b). These 
key events include 1) the covalent binding of the chemical to skin proteins (haptenation), 2) 
the release of pro-inflammatory cytokines and the induction of cyto-protective pathways in 
keratinocytes, 3) the maturation and mobilisation of dendritic cells (DC), immuno-
competent cells in the skin, and 4) the antigen presentation to naïve T-cells and 
proliferation of memory T-cells. Considerable progress has been made in recent years 
towards the development of alternative non-animal methods that address these key 
mechanisms. Following the ESAC peer review of the validation studies and the publication 
of the EURL ECVAM Recommendations on the in chemico Direct Peptide Reactivity Assay 
(DPRA) (EURL ECVAM 2013b), and the in vitro KeratinoSensTM test method (EURL ECVAM 
2014a), OECD Test Guidelines on these two non-animal methods have been recently 
adopted (TG 442C, OECD 2015a and TG 442D, OECD 2015b). 
4) There is general agreement that it is unlikely that alternative (non-animal) methods 
designed to address a single key event of the skin sensitisation pathway will be able to 
provide sufficient information to fully replace the use of animals for this endpoint (Adler et 
al., 2011). Instead, what is likely needed is some combination of information from 
complementary alternative methods (Jowsey et al., 2006; Adler et al., 2011). Against this 
background, activities are being pursued by academia, industry and the European 
Commission to evaluate mechanistically-based test methods that can contribute to skin 
sensitisation hazard identification and characterisation. 
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5) In 2008, EURL ECVAM received a joint submission by Kao Corporation and Shiseido (Japan) 
on the h-CLAT test method that described the extensive work performed to develop and 
optimise the method. This included the results of multiple laboratories studies (Sakaguchi et 
al., 2006, 2010; Ashikaga et al., 2006, 2008; Kosaka et al., 2008; Sono et al., 2008; Mizuno et 
al., 2008) and h-CLAT data for 100 chemicals. As a consequence, in the period between 
November 2009 and November 2012, EURL ECVAM coordinated a validation study on the h-
CLAT (EURL ECVAM 2013c). The study was designed to generate information according to 
the modular approach to validation (Hartung et al., 2004) with the primary objective of fully 
assessing the reliability of the h-CLAT (i.e. its transferability and within and between 
laboratory reproducibility). Only as a secondary study objective, the experimental data 
generated were used to perform a preliminary evaluation of the ability of the h-CLAT to 
discriminate between skin sensitising and non-sensitising chemicals, as defined by the 
United Nations (UN) Globally Harmonised System (GHS) to classification and labelling (UN 
GHS, 2013). Assessment of the preliminary predictive capacity of the h-CLAT was performed 
as a step towards determining the potential contribution of the method within integrated 
approaches to skin sensitisation hazard assessment. In addition, where possible, the 
experimental data were used to derive preliminary considerations on the ability of the test 
method to sub-categorise sensitising chemicals, e.g. into sub-categories 1A and 1B as 
defined by the UN GHS. 
6) Following completion of the study and finalisation of the Validation Study Report (EURL 
ECVAM, 2013c), EURL ECVAM requested the ECVAM Scientific Advisory Committee (ESAC) 
to provide an ESAC Opinion on the study. The ESAC Working Group (WG) "Skin 
Sensitisation" prepared a detailed WG report (EURL ECVAM, 2013d) which formed the basis 
of the ESAC Opinion (EURL ECVAM, 2014b; see Annex 1), endorsed by members at an ESAC 
meeting in March 2014 and formally delivered to EURL ECVAM in May 2014. 
 
2. Test Method definition  
7) The important role played by Dendritic Cells (DC) in the initiation of adaptive immune 
responses is well established, including the cutaneous immune response to chemical 
allergens. DC can recognise and internalise antigens such as haptenated proteins, transport 
them via the lymphatic system to the regional lymph nodes and present them via major 
histocompatibility complex (MHC) molecules to naïve T lymphocytes to induce 
differentiation and proliferation of specific memory T-cells. Recognition and processing of 
the antigen by DC requires the local production of various danger signals including 
inflammatory mediators resulting from the activation of the innate immunity of the skin 
(Ainscough et al., 2013; Kaplan et al., 2012; Vocanson et al., 2009). Once activated, DC 
migrate from the skin to the lymph nodes and undergo a process of maturation 
characterised by phenotypic and functional changes resulting in the loss of their capability 
to process antigens and in the acquisition of the functionality of antigen presentation.  The 
maturation process involves the decrease of phagocytic activity, increased expression of 
MHC molecules on the cell surface, changes in cytokines and chemokines secretion and up-
regulation of several co-stimulatory (e.g. CD80, CD86, and CD40) and intercellular adhesion 
molecules (e.g. CD11a, and ICAM-1/CD54) (Quah and O'Neill, 2005; Vocanson et al., 2009; 
Kimber et al., 2011).  
Some of these biomarkers have been considered in the development of cell-based assays 
for assessing the skin sensitisation potential of chemicals (Aiba et al., 1997; Casati et al., 
2005; dos Santos et al., 2009; Vandebriel et a.l., 2010). It is recognised that the mechanisms 
that lead in vitro to the augmentation of these membrane markers by sensitising chemicals 
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may only partially reflect the complexity of the mechanisms inducing DC maturation in 
integral biological models such as rodents and humans (Kimber et al., 2011; 2013). 
However, assays based on human myeloid cell lines and measuring markers known to be 
over-expressed during DC maturation in vivo, are considered to provide mechanistic 
information that can contribute to the in vitro assessment of the skin sensitisation potential 
of chemicals (OECD 2012a; 2012b; Adler et al., 2011;  Vanderbriel et al., 2010; van Helden et 
al., 2008) . 
8) In the h-CLAT method the modulation of the CD86 and CD54 membrane markers in THP-1 
cells (Tsuchiya et al., 1980), a human monocytic leukemia cell line used as a surrogate model 
for DC (van Helden et al., 2008), is measured by flow cytometry following 24 hours of 
exposure to eight serial concentrations of test chemical selected on the basis of a pre-
determined CV75 (i.e. the concentration of test chemical that allows 75% of cell survival). 
The h-CLAT test method is designed to discriminate between sensitising and non-sensitising 
chemicals whereby chemicals are classified as sensitisers if the relative fluorescence 
intensity (RFI) of either CD86 and/or CD54 exceeds a defined threshold (i.e. RFI CD86≥150 
and RFI CD54≥200; Sakaguchi et al., 2009) compared to the vehicle control wells at any 
tested concentration, in at least two out of three independent measurements (i.e. 
repetitions). Cell viability is measured concurrently by Propidium Iodide (PI) staining and RFI 
values are considered for the prediction only if cell viability is above 50%. 
9) Since the THP-1 cells are exposed to 8 serial concentrations of test chemicals, for positive 
chemicals it is generally possible to calculate from the concentration-response curve an 
Estimated Concentration (EC) 1  value for the CD86 and the CD54 representing the 
concentration of test chemical needed to induce an RFI equal to the respective threshold 
values, i.e. CD86 EC150 and CD54 EC200. Proposals have been made on how to use these 
values for potency prediction (Nukada et al., 2011, 2013), nevertheless additional work is 
still required to determine how h-CLAT data may inform potency assessment. 
10) As a result of the validation study a revised and more detailed Standard Operating 
Procedure (SOP) was defined (EURL ECVAM, 2013c) which EURL ECVAM will disseminate, 
together with a comprehensive description of the h-CLAT method through its database on 
alternative methods (DB-ALM, see http://ecvam-dbalm.jrc.ec.europa.eu; protocol  No. 158). 
The SOP contains all the necessary technical details (including electronic data reporting 
templates) needed by an end-user laboratory to implement it in a reliable and self-sufficient 
manner. In addition, EURL ECVAM intends to make available an online video tutorial with 
practical demonstration of how to perform the most critical steps of the h-CLAT SOP. 
 
3. Overall performance of the h-CLAT test method 
Reference data  
11) A key criterion employed for selecting the validation test chemicals was availability of high 
quality in vivo data from the murine LLNA and GPMT or Buehler test, with concordant 
classification from these assays. In addition, chemicals with available human data and/or 
which are known to produce misleading responses in the animal tests (e.g. Nickel chloride 
and Xylene which produce false negative and false positive responses in the LLNA test, 
                                                        
1
 Estimated Concentrations are not to be confused with Effect Concentrations which are also usually 
abbreviated "EC". 
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respectively) were considered in the selection. The set of chemicals used in the study 
comprised one third of non-sensitisers and two thirds of sensitisers, with a balanced 
representation of potency classes (weak, moderate, strong and extreme) for the sensitisers. 
Also included in the reference set were: chemicals from the LLNA performance standards 
(OECD 2010a), two well characterised pre-haptens (i.e. chemicals requiring abiotic 
activation to exert their sensitisation potential), 4-Phenylendiamine and R(+)-Limonene, a 
well-known pro-hapten (i.e. a chemical requiring metabolic activation to act as sensitiser), 
Dihydroeugenol, to challenge the potential of THP-1 cells to metabolically activate inert 
substances, and two metal salts, Berillium sulphate and Nickel chloride. Additional details 
on chemical selection can be found in the Validation Study Report (EURL ECVAM, 2013c). 
12) When interpreting the data from alternative non-animal methods such as the h-CLAT that 
have been largely developed and validated using animal reference data such as LLNA or 
GPMT, it should be kept in mind that the animal tests are not fully reflective of the human 
situation. Notably, an evaluation of the LLNA in comparison to human data has shown an 
accuracy of about 72% (Anderson et al., 2011) indicating an appreciable risk of both false 
negative and false positive predictions for humans. Moreover there is indication that the 
LLNA is deficient in detecting low to moderate sensitisers as well as metals and organometal 
compounds (EC, 2000). 
Transferability 
13) EURL ECVAM concludes that the h-CLAT test method is transferable to laboratories 
sufficiently experienced in cell culture techniques and flow cytometry analysis and that have 
received proper training. The h-CLAT procedure is composed of several tasks which need to 
be performed sequentially, i.e., the qualification of the cell batch, the determination of an 
accurate CV75 value, the cell staining and measurement of CD86 and CD54 expression by 
flow cytometry and the data analysis and interpretation. EURL ECVAM recommends 
therefore that a step-wise approach similar to the one implemented in the transferability 
phase of the validation study is used when implementing the method before the test is 
performed for routine testing.  
Reproducibility 
14) The between laboratory reproducibility, assessed in the validation study by testing a set of 
24 coded chemicals and determining concordant predictions of sensitiser versus non-
sensitiser, met the expected value of 80% set a priori by the Validation Management Team 
(VMT). The overall within laboratory reproducibility (calculated from 15 of the 24 chemicals 
tested) was found to be 80%, which was lower than the expected value of 85% set by the 
VMT.  
15) ESAC raised concerns in relation to within laboratory reproducibility since the VMT target 
value was not met. EURL ECVAM acknowledges this but notes that the VMT targets were 
derived from quite limited historical data on between laboratory reproducibility only, 
generated under non-blinded conditions (Sakaguchi et al., 2010). EURL ECVAM believes that 
these VMT target values should not be interpreted as 'cut-off' validation criteria since what 
can be considered as acceptable in terms of reproducibility typically depends on the context 
of use, such as within an IATA. However, as with data from any other experimental method, 
the reproducibility of h-CLAT needs to be taken into account when it is applied in any 
decision-making context. In this respect, it is worth noting that the reproducibility of the h-
CLAT for discriminating between skin sensitisers and non-sensitisers appears to be 
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comparable to that of the LLNA (i.e. 70-80%, as calculated from the data available in the 
NICEATM database, see: http://ntp.niehs.nih.gov).  
16) The ESAC peer review of the h-CLAT study included valuable expert discussion of various 
statistical approaches to assess within and between laboratory reproducibility. As a follow-
up, EURL ECVAM proposes to re-analyse the data from the validation study with a view to 
exploring the merits of various statistical methods for describing the reproducibility of a test 
method that produces a classification-based prediction. 
17) As indicated by the ESAC, further fine-tuning of the h-CLAT testing protocol and additional 
characterisation of the test system (THP-1 cells) may lead to an improved performance of 
the test method including the level of reproducibility that can be achieved. Nevertheless, 
the validation of the h-CLAT did not highlight any specific feature of the test method that 
would require additional optimisation in the short term to substantially improve its 
performance. 
Predictive Capacity 
18) Full evaluation of the predictive capacity of the h-CLAT was not within the scope of the EURL 
ECVAM study since the test method is not proposed as a stand-alone full replacement 
method. Nevertheless, the accuracy of the h-CLAT in predicting the in vivo classification 
(sensitiser/non-sensitiser) determined on the basis of concordant results in the LLNA, 
guinea pig tests and where available human data (see paragraph 11), was determined as 
76% (sensitivity 81% and specificity 66%) (EURL ECVAM, 2013c). A recently published study 
that reported data on 143 chemicals (Takenouchi et al., 2013) suggested an accuracy of 80% 
in predicting LLNA classifications indicating that the actual performance of the h-CLAT test 
in discriminating between sensitisers and non-sensitisers may thus be actually higher. The 
accuracy of the h-CLAT in predicting human skin sensitising potential is indicated in the 
scientific literature to be 83% (sensitivity 88%, specificity 67%) for a set of 66 chemicals for 
which human patch test data and case reports are available (Nukada et al., 2011) and for a 
smaller set of chemicals (n=23; sensitivity 81%, specificity 86%) (Bauch et al., 2011). 
 
4. Limitations 
4.1 Technical limitations 
19) Solubility of test substances: The test chemicals should be dissolved in a solvent compatible 
with the cell culture conditions. Therefore, chemicals which are not soluble in either 
medium, saline or DMSO, these being the solvents prescribed by the SOP, cannot be tested 
in the h-CLAT assay.  
20) Test substance stability: As with many in vitro and in chemico assays, chemicals which are 
not stable in the prescribed solvents because of hydrolysis or other chemical reactions 
cannot be reliably tested.  
21) Maximum testable concentration: In order to prevent osmotic stress of the cells, the 
maximum concentration of test substance should not exceed 5000 µg/mL.  
22) Interference with flow cytometry analysis: Since the h-CLAT uses a fluorescein 
isothiocyanate (FITC)-labelled antibody, strong fluorescent test chemicals emitting at the 
same wavelength as FITC may interfere with the flow cytometry light-signal acquisition.  To 
circumvent the problem, antibodies labelled with alternative fluorescent dyes may be used 
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provided that it can be shown that equivalent results to those obtained with the FITC-
labelled antibodies are obtained. Also, flow cytometry analysis cannot be conducted 
correctly in the case of excessive cytotoxicity due to artefacts arising from diffuse labelling 
of cytoplasmic structures.  
4.2 Limitations with regard to applicability  
23) A recently published analysis of h-CLAT data suggests that chemicals with an octanol-water 
partition coefficient (log Kow) value lower than 3.5 can be tested in the assay and provide 
accurate predictions, whereas chemicals with a log Kow greater than 3.5 tend to produce 
false negative results (Takenouchi et al., 2013). For this reason, it was suggested that 
positive h-CLAT predictions obtained with chemicals with a log Kow greater than 3.5 are 
likely to be trustworthy whereas a negative prediction should be considered inconclusive. 
24) As for many other assays based on an individual cellular model, the metabolic capacity 
(biotransformation) of the h-CLAT only partially represents the skin metabolism in vivo 
(Hennen et al, 2011; Chipinda et al., 2011; Fabian et al., 2013). Therefore, pro-haptens such 
as Isoeugenol may not be correctly identified by the assay.  Nevertheless, putative pro-
haptens such as 2-Aminophenol, Eugenol, 1-Naphtol and 2-Methoxy-4-methylphenol 
(Gerberick et al., 2009) have been reported in the h-CLAT submission to EURL ECVAM as 
being correctly predicted by the assay. In addition, Dihydroeugenol, a well characterised 
pro-hapten, was correctly classified as a sensitiser by all of the laboratories participating in 
the validation study (EURL ECVAM, 2013c). 
25) Some pre-haptens are reported to be false negative in the h-CLAT (e.g. Abietic Acid) 
whereas others are reported as being correctly predicted by the assay (e.g. Geraniol and 
Linalool) (Ashikaga et al., 2010). The two pre-haptens evaluated in the EURL ECVAM 
validation study, 1,4-Phenylendiamine and R(+)Limonene, were correctly detected as 
potential sensitisers by all of the laboratories.  
26) Most of the misclassifications generated by the h-CLAT in the EURL ECVAM study (EURL 
ECVAM 2013c), and in other published studies (Ashikaga et al., 2010) concerns chemicals 
that are weak sensitisers in vivo while the false negative rate for strong sensitisers is much 
lower. This should be kept in mind when interpreting negative results. 
 
5. Suggested regulatory use 
27) Due to the complexity of the mechanisms underlying skin sensitisation, it is likely that 
information from different methods (in silico, in chemico, in vitro) is needed to reduce or 
replace the need for animal testing, both for hazard identification and potency 
characterisation purposes.  
28) Based on the validation study results and other available information, the h-CLAT test 
method appears to be effective in providing information on the ability of a chemical to 
enhance the expression of the CD54 and/or CD86 cell membrane markers in THP-1 cells. 
Such markers are considered useful readouts for the identification of skin sensitising 
chemicals (OECD 2012a; 2012b). In addition, evidence in the literature clearly indicates the 
predictive value of h-CLAT data when combined with complementary information (Bauch et 
al., 2012; Nukada et al., 2013; Hirota et al., 2013; Tsujita-Inoue et al., 2014; van der Veen et 
al., 2014). Therefore results from the h-CLAT assay can be used within an IATA to determine 
the sensitisation potential of chemicals.  
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29) Taking into consideration the concentration-response information generated by the assay, it 
is plausible that h-CLAT may potentially contribute within an IATA to the characterisation of 
skin sensitisation potency. The extent of additional evidence needed to complement a h-
CLAT result will depend on the intended application (e.g. hazard identification or potency 
assessment) and context (availability and quality of other information). Examples of the use 
of h-CLAT data in integrated non-animal approaches for hazard and potency assessment 
have been published in scientific literature (Bauch et al., 2012; Nukada et al., 2013; Hirota et 
al., 2013; Tsujita-Inoue et al., 2014; van der Veen et al., 2014). 
30) Negative h-CLAT results should be interpreted with care, taking into due consideration (1) 
the limited capacity of the assay to metabolise (biotransform) pro-haptens, (2) the fact that 
some pre-haptens may not be sufficiently oxidised under the h-CLAT experimental 
conditions, and (3) the high rate of false negative predictions obtained with chemicals with 
a log Kow greater than 3.5.  
31) Employed within an appropriate IATA, the h-CLAT assay may be useful to satisfy information 
requirements for Cosmetics (Regulation EC/1223/2009), Chemicals (Regulation 
EC/1907/2006), Biocides (Regulation EC/528/2012) and Plant Protection Products 
(Regulation EC/1107/2009).  
 
6. Follow-up activities recommended by EURL ECVAM 
32) When applying the h-CLAT method, EURL ECVAM recommends that the revised protocol 
available at EURL ECVAM's DB-ALM service (http://ecvam-dbalm.jrc.ec.europa.eu, protocol 
No. 158) be used. 
33) EURL ECVAM will undertake additional statistical analysis of the validation study results to 
better describe and understand aspects of reproducibility of this method. 
34) Further testing to assess the performance of the h-CLAT method should include emphasis 
on assessing pre-and pro-haptens. In addition, its applicability to chemical mixtures and 
polymers (Jung YS et al., 2011) should be further investigated. 
35) Predictive capacity of the assay for the discrimination between sensitisers and non-
sensitisers should be further evaluated in the context of its inclusion within IATA. When 
doing so, the limitations of available reference data e.g. from LLNA (EC, 2000) with regard to 
reproducibility and relevance to the human situation should be however kept in mind.  
36) Integrated approaches using the h-CLAT method should also make use of other information 
sources, in particular from testing and non-testing methods (e.g. chemoinformatics, read-
across and QSAR models). In silico methods that incorporate metabolic considerations (e.g. 
TIMES-SS: Patlewicz et al., 2007) may also help to identify pre- and pro-haptens. Analogues 
which have a similarly predicted mechanism of action, e.g. based on protein binding, can be 
found using the OECD QSAR Toolbox (www.qsartoolbox.org). The Toolbox also includes a 
specific profiler based on the h-CLAT assay. A variety of proposals concerning the use of h-
CLAT data in combination with other information sources to discriminate between 
sensitising and non-sensitising chemicals have been published (Bauch et al., 2012; Nukada 
et al., 2013; van der Veen et al., 2014) and may support further work.  
37) The possible contribution of h-CLAT CD86 EC150 and CD54 EC200 values derived from the 
concentration-response curve to support sub-categorisation of sensitisers according to GHS 
(i.e. sub category 1A and 1B) and to contribute to potency assessment should be evaluated 
in the context of integrated approaches. Examples are published in the scientific literature 
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on how these values can contribute to both purposes (Ashikaga et al., 2010; Hirota et al., 
2013; Nukada et al., 2013; Tsujita-Inoue et al., 2014). For such evaluation, the use of human 
reference data (Basketter et al., 2014) will be particularly useful. 
38) To reduce the cost and time needed for deriving a h-CLAT prediction for the purpose of skin 
sensitisation hazard identification, consideration should be given to adapting the h-CLAT 
SOP to eliminate the need for a third run in case of consistent and unequivocal predictions 
in the first two runs. 
39) EURL ECVAM supports the development of an OECD Test Guideline for the h-CLAT. As this 
test may be best employed in combination with complementary methods, it should be 
considered in the current initiative being undertaken at OECD to develop a guidance 
document on IATA for skin sensitisation.  
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Summary of the ESAC Opinion  
The ESAC was requested to provide a scientific opinion on an EURL-ECVAM led validation study 
assessing mainly the transferability and reproducibility (within- and between-laboratories) of the h-
CLAT test method (primary objective of the study) in view of its possible future use as part of a non-
animal testing strategy for skin sensitization. The study had also been designed to provide 
preliminary information on a) the predictive capacity of the test method and b) its potential use for 
contributing to sub categorisation of sensitizing chemicals.  
Overall, the conclusions made by the ESAC based on the ESAC WG report correspond well with the 
conclusions drawn by the Validation Management Group overseeing the study and as described in 
the Validation Study Report, indicating that, generally, the conclusions are supported by the results 
shown in the report (see Section 15.1).  
 
The ESAC disagreed, however, with the VMG conclusion concerning the Within Laboratory 
Reproducibility (WLR). 
- Acceptance criteria were determined at the start of the study by the VMG. WLR was assessed 
using 15 chemicals in three independent experiments. The average reproducibility of 80% 
(KAO (86.7%), Shiseido (80.0%), EURL-ECVAM (80.0%) and Bioassay (73.3%)) did not meet the 
85% reproducibility target set by the VMG. Actually, only one out of four participants met 
this target. Despite missing the expected performance level, the VMG nevertheless 
concluded that the h-CLAT is a reproducible method within laboratories. This conclusion was 
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partly based on the premise that a subset of chemicals consistently drove the discrepancies 
in reproducibility, and that some of these problem chemicals might fall outside the 
applicability domain.  While the chemical limitations of the test are appreciated, the ESAC is 
concerned that there may be other inherent characteristics or critical aspects of the h-CLAT 
test method, which could be important sources of variability (e.g. the time course for 
expression of the cell surface markers; the state of cell differentiation be a source of 
variability). The other reason given by the VMG to support their conclusion is that the h-CLAT 
assay is intended to be used as part of an ITS. Generally, the ESAC does not support this 
reasoning: a low reproducibility, i.e. high variability will cause problems when using a test 
method in practice and this is independent of whether it is used as a stand-alone test 
method or within integrated approaches. Other information sources within an integrated 
approach will not be able to remedy the intrinsic variability of one information source. With 
regard to the h-CLAT assay, the ESAC Working Group is concerned that the poor 
reproducibility of the assay may actually create difficulties with respect to the interpretation 
of data generated as part of an ITS, as results are likely to be conflicting.   
- The data were considered strong enough to support transferability of the test to properly 
equipped, trained and staffed laboratories with the appropriate analytical capabilities.  
- Five of the 24 chemicals produced a discordant classification by the laboratories resulting in 
an average BLR reproducibility of 81.3%, meeting the target (80%). 
- For S/NS classification, values (accuracy: 76%; sensitivity: 81.3%; specificity: 65.6%) are, 
overall, lower than the values (84%, 87%, 75%, respectively) resulting from the historical data 
on 100 chemicals (Ashikaga et al., 2010), which were provided to EURL-ECVAM as part of the 
test submission. Due to this discrepancy the ESAC concludes that the number of substances 
and the information available for these substances in the peer reviewed publication was 
insufficient for allowing more than a purely preliminary indication on the predictive capacity 
in terms of S/NS.   
- For sub-categorization, the data generated and statistically assigned cut-offs propose a 
maximum accuracy of 58% accuracy, which is in contrast to previously published data 
(N=100) that reported an accuracy of 72% (Ashikaga et al. 2010). The ESAC does not 
understand why the VMT considers the values obtained in the validation study as promising. 
Our conclusion is that the number of substances and the information available for these 
substances was insufficient for allowing more than a purely preliminary indication on the 
predictive capacity in terms of potency classification.  
- The number of chemicals did not allow us to draw conclusions about the applicability domain 
of the test (which, notably, was not one of the study objectives). Empirically the applicability 
domain seems to exclude pro-haptens, auto-fluorescent compounds, chemicals with limited 
water solubility/stability, metal salts and volatile compounds. However, pre-/pro-haptens 
were reported as correctly identified.  
 
The predictive capacity, applicability domain and limitations of the test are not, in our view, yet fully 
defined.  The submitted study does not provide strong evidence supporting the usefulness of the h-
CLAT for GHS sub-categorisation of sensitizers. However, recent studies substantiate the preliminary 
data of the VSR (Nukada et al., 2012; Nukada et al., 2013).  
- The ESAC recommends that the sources of the unsatisfactory WLR (below the 85% target) be 
identified and addressed; 
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- better defining (1) the predictive capacity and (2) the applicability domain of the h-CLAT (to 
eliminate the uncertainty currently associated with a negative result) either through further 
testing (i.e. prospective validation) or through retrospective analysis of existing information 
(retrospective validation: data grouping / meta-analysis); 
- to adapt the SOP to reduce resource costs by eliminating the need for a third evaluation run 
in case where the first two runs are consistent;  
- to reassess the amended SOP version 7 using existing/historical results with the purpose to 
re-evaluate the predictive capacity of this test method.  
- that further studies be conducted to determine the potential of the test method to properly 
sub-categories chemicals with skin sensitisation potential. 
Recently, Nukada et al. (2013) reported a data integration strategy including the h-CLAT, the Direct 
Peptide Reactivity Assay (DPRA) and the knowledge-based expert system 'DEREK' for the 
development of a test battery to predict the skin sensitizing potential and potency of chemicals. 
Using a tiered strategy of h-CLAT and DPRA an accuracy of 86% and 73% for the potential and 
potency prediction, respectively, was obtained. Further studies are needed to identify the best 
integrated testing strategy or strategies able to address the different regulatory goals and risk 
assessments (hazard identification, classification, potency assessment, etc.) in reliable and relevant a 
manner.  
 
 
1. Mandate of the ESAC 
 
The opinion of ESAC should support ECVAM with respect to the development of recommendations 
regarding the reliability (transferability, within and between laboratory reproducibility) of the h-CLAT 
and the potential regulatory use of the test method. 
1. Study design – transferability, reliability and relevance  
 The ESAC was requested to review whether the validation study was conducted 
appropriately in view of the objective of the study:  
 Reproducibility of the h-CLAT method within laboratories (WLR); 
 Transferability;  
 Reproducibility between laboratories (BLR); 
 Predictive capacity of the test method. 
 
 With respect to the design and conduct of the study, the following issues were to be 
addressed: 
 Clarity of the test definition (module 1)  
 Clarity of the definition of the study objective  
 Appropriateness of the study design in view of study objective 
 Appropriateness of the study execution: 
 Appropriateness of the statistical analysis used for analysing WLR, transferability, BLR 
and (preliminary) predictive capacity. 
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2. Conclusions of the study 
 The ESAC was requested to assess the justification and plausibility of 
 Reproducibility (WLR and BLR) and transferability; 
 Preliminary predictive capacity; 
 Possible gaps between study design and study conclusions which remain to be 
addressed in view of the suggested conclusions/use; 
 Applicability and possible limitations of the test method, in particular in view of its 
potential use within an ITS for sensitisation testing and assessment. 
 
3. The ESAC is requested (a) to evaluate, on the basis of the data submitted in the validation study, 
the possible use of the test method (also within a strategy) to identify skin sensitizers, (b) to make 
additional recommendations (as required) on the proper scientific use of the test method within such 
a strategy taking specific aspects of this method into account (e.g. applicability, limitations etc.) and 
(c) to identify possible further information required (i.e. are there gaps) to be able to conclude on the 
plausibility of the suggested use (including within an ITS). 
 
 
2. Detailed opinion of the ESAC 
The ESAC was asked to provide an opinion on a EURL-ECVAM-coordinated study assessing the 
transferability and reproducibility (within- and between-laboratories) of the h-CLAT (primary 
objective of the study) in view of its possible future use as part of a non-animal testing strategy for 
skin sensitization. The study had also been used to provide preliminary information on a) the 
predictive capacity of the test method and b) its potential use for contributing to sub-categorisation 
of sensitizing chemicals.  
1) Study design – transferability, reliability and relevance. 
 The Test Definition of the h-CLAT assay would benefit from a more detailed rationale 
behind the selection of the THP-1 cell line, and CD86 and CD54 membrane markers; in 
particular as to why both of the markers are required. Furthermore, their biological and 
mechanistic relevance to the human situation is not sufficiently explained. There is 
ample evidence showing that CD86 and CD54 are generally up-regulated in response to 
challenges that cause cell damage, inflammation and cytotoxicity. There is a need to 
explain what special features of the test or the prediction model are making the test 
specific for sensitization. 
 The WLR was assessed at the level of concordance with a binary prediction (S/NS). An 
average reproducibility of 80% did not meet the 85% reproducibility target set by the 
VMG. Actually, only one out of the four participating laboratories  met this target. The 
definition of the reproducibility target (85%) set by the VMG was based on the 
performance of methods previously evaluated at EURL-ECVAM. The expected 
performance of the test (WLR) is derived from the BLR calculated from the test 
submissions. The ESAC does not consider 85% to be an unreasonably high target. 
Furthermore, the explanation offered according to which it was a small number of 
compounds with special properties that caused problems with reproducibility was not 
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further substantiated. Indeed, it was noted that the problem concerned 9 out of 15 
chemicals and none of the problem chemicals gave issues in all 4 laboratories.  
 The ESAC is concerned, in the absence of evidence, that low WLR was caused by the 
characteristics of the chemicals tested and that there may be inherent characteristics of 
the h-CLAT, which could be important sources of WLR variability The low reproducibility 
of the test, raised also the concern that the h-CLAT as potential ITS building block with 
poor reproducibility might actually create more difficulties in interpreting data as part of 
an ITS due to conflicting results.  
 The training and transfer phases of the validation study were well planned and executed. 
All the stages appear well documented. Some key issues have been identified during the 
process of transfer to the naïve laboratories and effort has been put into identifying and 
solving these issues. These changes were taken up in SOP version 5 (used for transfer) 
and resulted in SOP versions 6 and 7. It is clear from the transfer data that adopting this 
method in a laboratory requires sufficient experience in flow cytometry and cell culture.  
 The BLR was assessed in terms of concordance in predictions. Two BLR values were 
generated by testing 24 chemicals, one comparing the consistency of the two naïve labs 
with the first lead lab and the second comparing them with the second lead lab. ESAC 
agreed with the VMG's conclusions with respect to the acceptability of the BLR because 
of the marginal difference between the lowest BLR (79.2%) and expected performance of 
80%. The chemicals that drove discrepancies in the BLR study were the same as those 
driving discrepancies in the WLR study.  The ESAC notes, in the absence of a defined 
applicability domain, that some of these test chemicals may have physicochemical 
properties making them incompatible with this test method. 
 The ESAC recognizes the fact that this study was not designed to address the predictive 
capacity of the h-CLAT due to the low number of chemicals. This also applies to the sub-
categorization. Three chemicals (methyl methacrylate, DCNB and benzyl alcohol) were 
consistently and reproducibly wrongly classified. 
 The project was described and designed in clearly recognizable and well described 
phases including Test Definition (Module 1), Transferability (Module 3), Within 
Laboratory Reproducibility (WLR) (Module 2), Between Laboratory Reproducibility (BLR) 
(Module 4). The data were also used for a preliminary evaluation of Predictive Capacity 
(Module 5).  
 Overall, the chosen statistical approach was considered appropriate. The ‘expected 
proportion’ of concordant classifications (between laboratories) was calculated to be 
90% on the basis of available data on between-laboratory reproducibility as submitted to 
ECVAM (see Appendix 2 of VSR, page 5). However, it was not clear why a power of 75% 
rather than the more conventional 80% or 90% power had been applied. This power 
allows for detecting 25% changes in each direction and, as a consequence, leads to a 
lower limit of the confidence interval of 65 % (90%-25%).  
2) Conclusions of the study 
 Overall, the study design, including the chemicals and their associated reference data, 
were considered appropriate for the purpose of addressing the first objective of the 
study: Assessing the WLR (N=15) and BLR (N=24) of the h-CLAT.  
 Overall, the conclusions made by the ESAC correspond well with the conclusions drawn 
by the VMG as described in the VSR, tending for confirm that these conclusions are 
supported by the results shown in the report.  
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 The ESAC disagreed, however, with the VMG conclusion concerning the WLR. An 
average reproducibility with the validation study test chemicals of 80% (not meeting the 
85% VMG reproducibility target) set by the VMG. Actually, only one out of four 
participating laboratories met this target. The validation study did not fully establish the 
reasons for the WLR performance figures obtained. 
 The conclusion on the BLR is considered reasonable in light of the marginal difference 
between the lowest BLR (79.2%) and expected performance of 80%. See above 
 The accuracy values for S/NS classification (76%) and sub-categorization (57%) are lower 
than those reported earlier (84% (S/NS) and 72% (sub-categorization)) and based on 
historical data on 100 chemicals (Ashikaga et al. 2010. ATLA 38; 275-284) which were 
submitted to EURL-ECVAM as part of the test submission. The ESAC believes this may be 
explained in part by the smaller number of chemicals used for the validation study, 
some of which were not part of the historical data set. A separate communication from 
the test developers suggests that the historical data may have contained 
proportionately fewer difficult chemicals (e.g. the three chemicals consistently wrongly 
classified in the validation study are not part of the 100 chemical set).  
Assessment/description of the applicability domain was not the objective of this study. 
Consequently, the small number of chemicals used in the validation study, which was set 
to satisfy the primary goal of the study, is not sufficient on its own to draw robust 
conclusions on the applicability domain. 
 
3) Possible use of the test method, i.e. to identify (also within a strategy) skin sensitizers, and 
additional recommendations (as required) on the proper scientific use of the test method within such 
a strategy. 
 As yet no applicability domain has been described for this method. Deciding whether or 
not a chemical falls within the applicability domain of the test will be a challenge with 
regard to pro-haptens, metal (salts), chemicals with limited solubility/stability in water, 
volatile compounds and auto-fluorescent compounds. 
 Regarding potency class, the data obtained did not support the use of the h-CLAT as a 
stand-alone assay for potency classification. This is in agreement with the statement of 
the VMG that the assay should be further evaluated for its capacity to "contribute" to a 
potency classification. 
Recommendations: 
 The ESAC considered that the target value for WLR was a realistic and justified one and 
were therefore concerned that three of the four laboratories failed to meet this target. 
The ESAC recommends that the sources of variability be identified (e.g. the time course 
for expression of the cell surface markers; the state of cell differentiation be a source of 
variability), and that solutions be provided. Poor reproducibility may create difficulties in 
interpreting data as part of an ITS due to conflicting results.  A review of the existing 100 
chemical/24 chemical datasets might identify properties of chemicals for which this test 
is not an appropriate method for investigating skin sensitisation potential.  
 The ESAC recommends better explaining, clarifying or defining  (1) the predictive capacity, 
the ability of the cell system and biomarkers to selectively identify skin sensitisation, and 
the sources of variability; and (2) the applicability domain of the h-CLAT to reduce the 
frequency to inconsistent results, either through further testing (i.e. prospective 
 
ANNEX 1 ESAC OPINION 
 
ESAC Opinion on the EURL ECVAM-led study of the human Cell Line Activation Test (h-CLAT) for skin 
sensitisation testing          
 
23 
validation) or through retrospective analysis of existing information (retrospective 
validation: data grouping / meta-analysis).  
 For greater efficiency, the SOP could be adapted by eliminating the need for a third 
evaluation run in case where the first two runs are consistent as a third inconsistent run 
does not change the outcome. 
 Based on the ESAC assessment of the validation study data, the available limited 
evidence does not support the use of the test method for GHS sub-classification of 
sensitizers: that was not, however, a primary objective of the validation study. Additional 
information and evidence are required when further consideration is given to the use of 
the test method for this purpose (see for example Nukada et al., 2012; 2013). Nukada et 
al. (2013) reported a data integration strategy including HCLAT, DPRA and DEREK for the 
development of a test battery to predict the skin sensitizing potential and potency of 
chemicals. Using a tiered system of h-CLAT and DPRA an accuracy of 86% and 73% for the 
potential and potency prediction was obtained. The tiered system showed a higher 
sensitivity (from 88 to 96%) compared with h-CLAT alone. Further studies are needed to 
identify the best integrated testing strategy or strategies necessary to cover the different 
regulatory goals and risk assessments (hazard identification, classification, potency 
assessment, etc.).  
 
3. Informative background to the Mandate and Opinion 
 
Skin sensitisation is the toxicological endpoint associated with substances that have the intrinsic 
ability to cause Allergic Contact Dermatitis, ACD in humans. ACD represents the most common 
manifestation of immunotoxicity in humans, i.e. adverse effects of xenobiotics involving the immune 
system. The identification of the skin sensitization potential represents an important component of 
the safety assessment of any new substance and especially for those intended for topical application 
(e.g. cosmetics). Current regulatory predictive tests for skin sensitization rely on the use of animals, 
these include: 
a) the traditional guinea pig tests: Buehler Test and Guinea-pig Maximisation Test (OECD TG 
406, Ref.1),  
b) the Local Lymph Node Assay (LLNA, OECD TG 429, Ref.2) and its recently OECD adopted 
non-radioactive variants (OECD TG 422A, Ref.3 and OECD TG 422B, Ref.4).  
Despite the progress that has been made in the development of alternative methods for skin 
sensitisation hazard identification, there are currently no validated methods available. In addition 
none of the tests currently under development/evaluation is able to fully characterise the relative 
potency of sensitising substances and therefore, none of these assays is considered a stand-alone 
method, capable of fully replacing current animal procedures, in particular as regards to cosmetics.  
The current view therefore is to combine different test methods in order to address different key 
mechanisms of skin sensitisation: skin bioavailability, haptenation (the protein binding of chemicals 
which triggers immunological responses), epidermal inflammation, dendritic cell activation and 
migration, T cell proliferation. Test methods are currently under development which have been 
specifically designed to address these key mechanistic steps involved in skin sensitisation. Before 
these test methods can be routinely used, e.g. in ITSs, their capacity to produce reproducible results 
needs to be demonstrated as a first step. There is ample evidence showing that maturation markers 
in general, and CD86 and CD54 in specific, are generally up-regulated in response to challenges that 
cause inflammation and cytotoxicity. There is however a window in which only sensitizers (or the 
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majority of them) activate dendritic cells (DCs). Cellular stress induced by allergens is different from 
the one triggered by irritants. Furthermore, hypersensitivity reactions are the result of normally 
beneficial immune responses acting inappropriately against benign antigens, causing inflammatory 
reactions and tissue damage. Just for clarification, DCs are recognized as important antigen 
presenting cells in adaptive immunity because of their capacity to stimulate naïve lymphocytes 
(Banchereau et al., 2000). Langerhans cells (LC) are resident immature DCs in the skin capable to take 
up and process contact allergens. During this process LC differentiate into mature 
immunostimulatory cells up-regulating the expression of co-stimulatory molecules such as CD80, 
CD86 and CD40 and adhesion molecules including CD2, CD11a, CD54, CD58 (Quah and O’Neill, 2005). 
Activated LC move from the epidermis into the dermis, and into the regional lymphatic system. In the 
lymph node, LC differentiate into mature dendritic cells and present antigen to specific T lymphocyte 
using MHC class II molecules to hold the processed antigen in place. Adhesion molecules on both the 
antigen-presenting cell (i.e. CD86) and the T-cell (i.e. CD28) ensure appropriate contact and co-
stimulation. Following appropriate stimulus, a clone of T cells with the ability to react to the antigen, 
which caused their expansion, is produced. The h-CLAT it is a test method that allows for quantitative 
analysis of a chemical’s potential to induce activation of THP-1 cells (used as a surrogate for human 
myeloid dendritic cells). This method has been initially proposed by Ashikaga et al. (2002) to identify 
sensitizers, and Yoshida et al. (2003) reported that naïve THP-1 could respond to sensitizers 
specifically through augmented expression of co-stimulatory molecules, CD54 and CD86, and 
considered this as a possible tool to be used as an in vitro sensitization test.  
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
R1 ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES: Validation study addressing mainly reliability 
If R1)applies please specify further: 
►Prevalidation Study  
►Prospective Validation Study In the period between 2010 and 2012 EURL 
ECVAM coordinated a validation study focusing 
on an assessment of reliability of three test 
methods for skin sensitisation testing: 1) the 
Direct Peptide Reactivity Assay (DPRA), 2) the 
human Cell Line Activation Test (h-CLAT), 3) the 
Myeloid U937 Skin Sensitisation Test (MUSST).  
This request focuses on the h-CLAT test method. 
►Retrospective Validation Study  
►Validation Study based on Performance 
Standards 
 
R2 Scientific Advice on a test method submitted to 
ECVAM for validation  
(e.g. the test method's biological relevance etc.) 
 
R3 Other Scientific Advice  
(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells, definition of performance standards etc.) 
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2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
Validation of the reliability of the Human Cell Line Activation Test (h-CLAT) 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
1) Background to skin sensitization and current predictive tests. 
 
Skin sensitisation is the toxicological endpoint associated with substances that have the intrinsic 
ability to cause skin allergy, leading to the disease called allergic contact dermatitis (ACD) in humans.  
 
The identification of the skin sensitisation potential represents an important component of the 
safety assessment of new and existing substances including cosmetic ingredients. Current regulatory 
predictive tests for skin sensitisation rely on the use of animals. These include: guinea-pig tests 
(Buehler Test and Guinea-pig Maximisation Test) (TG 406, OECD 1992; TM B06, EC 2008a), the 
murine Local Lymph Node Assay (LLNA) (TG 429, OECD 2010a; TM B42, EC 2008a) and its non-radio-
isotopic variants (TG 422a, OECD 2010b; TG 422b, OECD 2010c).  
 
The key events underlying of the induction of skin sensitisation are well understood and have been 
recently documented by the OECD in its report on: “The Adverse Outcome Pathway (AOP) for Skin 
Sensitisation Initiated by Covalent Binding to Proteins” (OECD 2012a; 2012b). These include: 1) the 
ability of the chemical to penetrate the skin and reach the site of haptenation (skin bioavailability), 
2) the covalent binding of the chemical to skin proteins (haptenation), 3) the release of pro-
inflammatory signals and the induction of cyto-protective cellular pathways in keratinocytes 4) the 
activation and maturation of Dendritic cells (DC) the skin immunocompetent cells, 5) the migration 
of DC from skin to the regional lymph nodes, 6) the presentation by DC of the haptenated protein to 
T cells and the clonal expansion of memory T cells (lymphocytes capable of being stimulated and 
activated specifically by the haptenated protein).  
 
Progress has been made in recent years in the development of mechanistically-based alternative 
methods for hazard identification some of which might also be able to contribute to potency 
prediction. However, none of these tests is currently regarded to have the potential to function as a 
stand-alone method to fully replace the animal tests. Instead, it is proposed that a combination of in 
in silico, in chemico and in vitro tests, addressing the key biological events of skin sensitisation, will 
be needed to achieve this goal. 
 
Proposals on how to use these methods in Integrated Testing Strategies (ITS)/Integrated Approaches 
to Testing and Assessment (IATA) for both hazard identification and potency prediction are 
emerging.  
 
 
 
 
2) The Human Cell Line Activation Test (h-CLAT). 
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The Human Cell Line Activation Test addresses the role that Langerhans cell (LC) and dermal 
dendritic cells (DC) play in the induction of skin sensitization. These cells are important mediators in 
the skin sensitization process since they are capable of presenting the hapten-protein conjugate to 
responsive T lymphocytes in the lymph nodes draining the site of exposure (Kimber and 
Cumberbatch, 1992). The maturation process of LC and DC from antigen processing cells to antigen 
presenting cells is considered a key event in the acquisition of skin sensitisation. This maturation 
process involves the modulation of the expression of cell surface phenotypic markers, those most 
commonly reported being CD54, CD80, CD86 and major histocompatibility complex (MHC) class II 
(Galvao dos Santos et al., 2009). This knowledge has been exploited in the development of in vitro 
tests based on the use of DC-like immortalized cell-lines to screen the skin sensitization potential of 
chemicals. 
 
The h-CLAT measures the modulation of CD86 and CD54 protein markers on the surface of THP-1 
cells (human monocytic cell line) by flow cytometric analysis, following 24 hour cell exposure to 8 
concentrations of a test substance. The concentrations used in the main experiment are selected on 
the basis of the CV75 value, the estimated concentration of test substance yielding 75% cell viability, 
previously determined with a propidium iodide viability assay. A chemical is classified as sensitiser if 
the expression of either the CD86 and/or the CD54 is equal or exceeds a defined threshold in at least 
2 of 3 independent evaluations. 
 
The h-CLAT test method was jointly developed by Kao Corporation and Shiseido. Extensive 
development/optimisation/evaluation work including assessment of the test method’s performance 
in multi-laboratory ring trials was conducted prior submission to ECVAM. The submission to ECVAM 
reported results for 100 chemicals with an accuracy of 84% for distinguishing sensitisers from non-
sensitisers compared to LLNA data. 
 
3) Study objectives and design 
 
The validation of the h-CLAT test method was part of larger validation study involving the 
assessment of two other test methods, the Direct Peptide Reactivity Assay (DPRA) and the Myeloid 
U937 Skin Sensitisation Test (MUSST). The validation study was coordinated by ECVAM in the period 
between 2010 and 2012 with the primary objective of assessing the test methods’ transferability 
and within and between laboratory reproducibility in view of their potential future use in integrated 
non-animal approaches intended to reduce and replace the currently used animal tests for skin 
sensitisation hazard identification. 
 
As a secondary goal of the study, the experimental data were used to perform: 
 
a) A preliminary evaluation of the ability of the three tests to reliably discriminate skin sensitising (S) 
from non-sensitising (NS) chemicals as defined by the Globally Harmonised System (GHS) of 
classification and labelling of substances (category 1; no category) (UN, 2011) and as implemented in 
the European Commission Regulation on classification, labelling and packaging (CLP) of substances 
and mixtures (EC, 2008b). 
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b) Where possible, a preliminary consideration of the ability of the three tests to contribute to 
potency categorisation e.g. GHS sub-category 1A (strong sensitisers) and 1B (other sensitisers) as 
defined in the fourth revised edition of GHS (2011).  
 
24 coded test items were tested by each of the four laboratories participating in the study for the 
evaluation of the h-CLAT (Kao and Shiseido as the lead laboratories, Biossay and EURL ECVAM as the 
naïve laboratories) to generate information on the between-laboratory reproducibility. A subset of 
15 chemicals was tested two additional times in each laboratory for the evaluation of the within-
laboratory reproducibility. 
 
With respect to the ECVAM's modular approach to validation (Hartung et al., 2004) the study 
generated information on modules 1) test definition, 2) within laboratory reproducibility, 3) 
transferability and 4) between laboratory reproducibility. In addition, the experimental data 
contributed to modules 5) predictive capacity and 6) applicability domain. However, the number of 
chemicals used in this validation study, which was based on statistical considerations related to 
the evaluation of the reproducibility only, was not sufficient on its own to conclude on the last 
two modules. 
 
 
4) Study results 
 
The main results for the study’s primary goal are summarised in the table below: 
 
Module Results 
Module 2 
WLR 
Evaluation of the WLR for a subset (n=15) of the validation study 
chemicals in each laboratory focused on the concordance of predictions 
(sensitizer versus non-sensitiser) as determined by the results of three 
independent experiments.  
Kao Laboratory WLR=86.7% 
Shiseido Laboratory WLR=80% 
EURL ECVAM Laboratory WLR=80% 
Bioassay Laboratory WLR=73.3% 
Module 3 
Transferability 
Both naïve laboratories (EURL ECVAM and Bioassay) succeeded in 
transferring the protocol to their testing facilities. 
Module 4 
BLR 
Evaluation of the BLR for the 24 chemicals focused on the concordance 
of the predictions (sensitiser versus non-sensitiser) and was calculated 
by comparing the two naïve laboratories with each of the two lead 
laboratories separately. 
Naïve and Kao BLR=83.3% 
Naïve and Shiseido BLR=79.2% 
Overall BLR=79.2% 
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5) Conclusions of the VMG  
The VMG concluded that the information generated in this validation study demonstrates that the h-
CLAT is a robust test method that can be easily transferred to properly equipped laboratories 
sufficiently experienced in cell culture and flow cytometry analysis. In addition the study results 
support the fact that the h-CLAT is a reproducible test method that can contribute to the 
determination of the sensitization potential of substances. 
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does ECVAM 
require advice on 
the current issue? 
The opinion of ESAC should support EURL ECVAM with respect to the 
development of an EURL ECVAM recommendation on the h-CLAT assay 
outlining (1) the scientific basis of the assay, (2) its overall performance as 
assessed during the study and based on other (e.g. published) information, 
(3) its applicability and limitations. Furthermore, the advice of ESAC should 
support ECVAM with respect to the analysis of possible data gaps that need 
to be addressed in view determining the test method's potential use and 
usefulness within integrated approaches for skin sensitisation hazard and 
risk assessment. 
 
 
4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
1) DESIGN & CONDUCT OF STUDY: The ESAC is requested to review 
whether the study was conducted appropriately in view of the objective of 
the study. The study objective was to assess 
(1) the reproducibility of the h-CLAT method within one laboratory (WLR) 
(2) its transferability to other laboratories  
(3) its reproducibility between laboratories (BLR) 
(4) Furthermore, the study aimed at assessing, in a preliminary manner, the 
predictive capacity of the test method for distinguishing between 
sensitisers and non-sensitisers and, where possible, to appraise its potential 
to contribute to a further sub-categorisation of sensitisers into two 
subcategories (1A and 1B). 
 
When reviewing the design and conduct of the study, the following issues 
should be addressed in particular: 
(a) Clarity of the test definition (module 1)  
(b) Clarity of the definition of the study objective and study 
management 
(c) Appropriateness of the study design & execution in view of the 
study objectives, inter alia: 
o Is the number of tested chemicals (24) sufficient for the 
purposes of the study? 
 
ANNEX 2 ECVAM REQUEST FOR ESAC ADVICE 
35 
o Are the reference data used for assessing in particular the 
predictive capacity appropriate and of good quality? 
o Was the identification of chemicals conducted in an 
appropriate manner (i.e. presence or absence of selection 
criteria, justification etc.)? 
o Is the adverse effect range of the selected chemicals 
appropriate for the purpose of the study 
o In case of gaps (chemical class etc.) – are these justified? 
o Is the number of laboratories sufficient? 
(d) Appropriateness of the study execution (e.g. were there pre-
defined test acceptance criteria, were these respected? How were 
exceptions / deviations handled? Were provisions specified for 
retesting? Was the number of repetitions sufficient? etc.) 
(e) Appropriateness of the statistical analysis used for analysing WLR, 
transferability, BLR and (preliminary) predictive capacity. 
2) CONCLUSIONS OF STUDY: The ESAC is requested to assess whether the 
conclusions, as presented in the Validation Study Report, are substantiated 
by the information generated in the study and are plausible with respect to 
existing information and current views (e.g. literature). 
In particular:  
(a) Are the conclusions on reproducibility (WLR and BLR) as well as 
transferability justified and plausible? 
(b) Are the conclusions on preliminary predictive capacity justified and 
plausible with respect to existing information 
(c) Are there possible gaps between study design and study 
conclusions which remain to be addressed in view of the suggested 
conclusions / use (see also point 3)? 
(d)  Do the data generated with this defined set of chemicals together 
with available existing data provide sufficient information on the 
applicability and possible limitations of the test method, in 
particular in view of its potential use within an ITS for sensitisation? 
 
3) SUGGESTED USE OF THE TEST METHOD: The ESAC is requested (a) to 
evaluate, on the basis of the data summarised in the validation study 
report, the possible use of the test method (also within a strategy) to 
identify skin sensitisers, (b) to make additional recommendations (as 
required) on the proper scientific use of the test method within such a 
strategy taking specific aspects of this method into account (e.g. 
applicability, limitations, technical limitations etc.) and (c) to identify 
possible further information required (i.e. are there gaps) to be able to 
determine the potential use and usefulness of the test method within 
integrated approaches. 
 
4.3  TIMELINES 
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Timelines 
concerning this 
request 
When does 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: 4Q 2013 (probably through 
written procedure) 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
NO 
Request to be presented to ESAC at 
ESAC plenary meeting 
YES Final request presented at 
ESAC 38, 18/19 June 2013 
 
5.  ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN ESAC 
5.1  ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to ECVAM? 
(YES/NO) 
S1 ESAC Rapporteur NO 
S2 ESAC Working Group YES. 
However, no WG needs to be established, 
as EURL ECVAM has taken the decision to 
employ the existing ESAC WG 
"Sensitisation" (set up in 2011) also for the 
h-CLAT review. The WG has already 
prepared detailed reviews/draft opinions 
on the DPRA and the Keratinosens test 
methods. This will add consistency to the 
review of these three sensitisation test 
methods and expedite progress as, at the 
time of issuing this request (June 2013), 
the VSR is already available and the WG 
can therefore commence with the review 
work. 
Present ESAC WG: 
 Dr. Erwin ROGGEN (ESAC member, 
Chair of ESAC WG and rapporteur; 3Rs 
Management and Consultancy, 
Denmark) 
 Prof. A. Wallace HAYES (external 
expert; Harvard University, USA) 
 Dr. Maja ALECSIC (external expert, 
Unilever, UK) 
 Dr. Emanuela CORSINI (external expert; 
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Dipartimento di scienze farmacologiche 
e biomoleculari, Università Degli Studi 
di Milano, Italy) 
 Dr. David LOVELL (external expert; 
University of Surrey, UK) 
 Dr. Michael WOOLHISER (external 
expert; Dow Chemical Company, USA) 
 Prof. Yong HEO (external expert, 
ICATM nomination (KoCVAM); College 
of Natural Sciences, Catholic University 
of Deagu, South Korea) 
S3 Invited Experts  
Ad S3: If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above (S1-S3):   
 
 
5.2  DELIVERABLES AS PROPOSED BY ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other 
than ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
 
D2 ESAC Peer Review Report 
and draft opinion 
YES 
If other than above (D1-D2):  
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6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
Count Description of document Already available? 
(YES/NO) 
File name 
0 EURL ECVAM Validation Study Report YES h-CLAT Validation Study 
Report.pdf 
2 Appendices 1-15 to EURL ECVAM 
Validation Study Report 
YES h-CLAT appendices to 
VSR.pdf 
3 EURL ECVAM Strategy for Replacement 
of Animal Testing for Skin Sensitisation 
Hazard Identification and Classification 
YES EURL ECVAM strategy .pdf 
4 OECD Report: 
The Adverse Outcome Pathway for Skin 
Sensitisation Initiated by Covalent Binding 
to Proteins. Part 1 
YES OECD AOP-part1.pdf 
5 Publication: 
Progress on the development of human in 
vitro dendritic cell based assays for 
assessment of the sensitizing potential of a 
compound 
YES dos Santos 2009.pdf 
6 Publication: 
A Comparative Evaluation of In Vitro Skin 
Sensitisation Tests: The Human Cell-line 
Activation Test (h-CLAT) versus 
the Local Lymph Node Assay (LLNA) 
YES Ashikaga 2010.pdf 
7 Publication: 
Predicting skin sensitization potential and 
inter-laboratory reproducibility 
of a human Cell Line Activation Test (h-
CLAT) in the European Cosmetics 
Association (COLIPA) ring trials 
YES Sakaguchi 2010.pdf 
8 Publication 
Predictive performance for human skin 
sensitizing potential 
of the human cell line activation test (h-
CLAT) 
YES Nukada 2011 
9 Publication: 
Prediction of skin sensitization potency of 
chemicals by human Cell Line 
Activation Test (h-CLAT) and an attempt at 
classifying skin sensitization potency 
YES Nukada 2012a.pdf 
10 Publication: 
Data integration of non-animal tests for the 
development of a test battery 
to predict the skin sensitizing potential and 
potency of chemicals 
YES Nukada 2012b.pdf 
11 Publication: 
Predictive performance of the human Cell 
Line Activation Test (h-CLAT) for lipophilic 
chemicals with high octanol-water partition 
coefficients 
NO 
Will be made available 
as soon as possible 
Takenouchi et al.- 
Submitted for publication 
  
 
ANNEX 2 ECVAM REQUEST FOR ESAC ADVICE 
39 
7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
During its 38th meeting on 18/19 June 2013 the ESAC plenary decided to employ the ESAC Working 
Group "Sensitisation" for preparing a detailed scientific review of the study on the h-CLAT test 
method for skin sensitisation testing. 
 
7.2 TITLE OF THE ESAC WORKING GROUP 
Full title:  
ESAC Working Group on Skin Sensitisation Test Methods 
 
Abbreviated title: 
ESAC WG Sensitisation 
7.3 MANDATE OF THE ESAC WG 
The WG is requested to conduct a scientific review of the ECVAM-coordinated validation study 
focusing on an assessment of reliability of the h-CLAT test method. The review needs to address the 
questions put forward to ESAC by ECVAM. 
 
The review should focus on the appropriateness of design and conduct of the study in view of the 
study objective and should provide an appraisal to which extent the conclusions of the Validation 
Management Team (VMT) are substantiated by the information generated during the study and how 
the information generated relates to the scientific background available. 
 
7.4 DELIVERABLE OF THE ESAC WG 
The ESAC WG is requested to deliver to the ESAC Chair and the ESAC Coordinator a detailed ESAC 
Working Group Report outlining its analyses and conclusions. A reporting template has been 
appended (Appendix 1) intended to facilitate the drafting of the report. 
 
The conclusions drawn in the report should be based preferably on consensus. If no consensus can 
be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
 
7.5 PROPOSED TIMELINES OF THE ESAC WG 
The ESAC Coordinator has proposed timelines which should be agreed upon during the first 
Teleconference (Item 1 in the table): 
Item Proposed date/time Action Deliverable 
1 July 2013 1. Discussion of the mandate 
and first appraisal of the 
VSR.  
2. Agreement on further 
timelines and possible 
work distribution 
 
2 Friday 20. September 2013 Forwarding of initial  
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observations (within ESAC WG 
template) to ECVAM 
3 1 & 2 October 2013 ESAC WG meeting at JRC 
campus in Ispra, Italy 
Draft ESAC 
WG report 
4 End of November/mid 
December 2013 
Forwarding final report to 
ESAC Chair and ESAC 
Coordinator 
Final 
report, 
adopted by 
WG 
 
 
7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WG 
The ESAC WG is requested to address the questions posed to the ESAC which have been broken 
down further in more specific questions (see section 4.2). 
 
When preparing the final ESAC WG report to address these questions, the ESAC WG is requested to 
use a pre-defined reporting template. This template (see appendix 1) follows ECVAM's modular 
approach and addresses to which extent the standard information requirements have been 
addressed by the study. The template allows moreover for addressing the issues specific studies 
outlined in section 4.2. The Coordinator will provide guidance if necessary. 
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